2026-06-24 00:57:33
We are watching the birth of a new category of medicine:
proactive, multi-cancer, blood-based screening
that could make comprehensive cancer detection as routine as a cholesterol panel.
An entire industry is emerging around multi-cancer early detection.
Exact Sciences’ Cancerguard launched as a laboratory-developed test in September 2025.
Abbott is acquiring Exact Sciences for $21 billion
— a signal of how seriously the pharmaceutical industry takes this c…

